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ABSTRACT
Introduction Chronic, non- cancer, axial or radicular spinal 
pain is a common condition associated with considerable 
socioeconomic burden. Clinicians frequently offer patients 
various interventional procedures for the treatment of 
chronic spine pain; however, the comparative effectiveness 
and safety of available procedures remains uncertain.
Methods We will conduct a systematic review of 
randomised controlled trials that explores the effectiveness 
and harms of interventional procedures for the 
management of axial or radicular, chronic, non- cancer, 
spine pain. We will identify eligible studies through a 
systematic search of Medline, EMBASE, CINAHL, Cochrane 
Central Register of Controlled Trials and Web of Science 
from inception without language restrictions. Eligible 
trials will: (1) enrol primarily adult patients (≥18 years old) 
with axial or radicular, chronic, non- cancer, spine pain, 
(2) randomise patients to different, currently available, 
interventional procedures or to an interventional procedure 
and a placebo/sham procedure or usual care, and (3) 
measure outcomes at least 1 month after randomisation.
Pairs of reviewers will independently screen articles 
identified through searches and extract information 
and assess risk of bias of eligible trials. We will use a 
modified Cochrane instrument to evaluate risk of bias. 
We will use frequentist random- effects network meta- 
analyses to assess the relative effects of interventional 
procedures, and five a priori hypotheses to explore 
between studies subgroup effects. We will use the Grading 
of Recommendations Assessment, Development and 
Evaluation approach to assess the certainty in evidence 
for each outcome, including direct, indirect and network 
estimates.
Ethics and dissemination No research ethics approval 
is required for this systematic review, as no confidential 
patient data will be used. We will disseminate our findings 
through publication in a peer- reviewed journal and 
conference presentations, and our review will support 
development of a BMJ Rapid Recommendations providing 
contextualised clinical guidance based on this body of 
evidence.
PROSPERO registration number CRD42020170667.
INTRODUCTION
Chronic, non- cancer, spinal pain is defined as 
any painful condition, local (axial) to or radi-
ating from (radicular) the spine, that persists 
for more than 3 months and is not associated 
with a diagnosis of cancer.1 Chronic non- 
cancer pain is a complex and multifactorial 
condition that continues to be a significant 
health challenge worldwide, and is associated 
with considerable socioeconomic burden.2 In 
Canada, population- based surveys conducted 
between 1994 and 2008 suggest 15%–19% 
of adults live with chronic non- cancer pain,3 
with 21% related to spinal conditions.4 
Strengths and limitations of this study
 ► Our broad study eligibility criteria and consideration 
of trials in any language will increase generalisabil-
ity of our results.
 ► We will use the Grading of Recommendations 
Assessment, Development and Evaluation approach 
to evaluate our certainty in treatment effects.
 ► We will optimise interpretability by presenting risk 
differences and measures of relative effect for all 
outcomes reported, and by presenting findings for 
comparative effectiveness of interventional proce-
dures using a minimally- contextualised approach 
that considers effect estimates, precision and cer-
tainty of evidence.
 ► Our results will be limited by possible shortcomings 
of primary studies.
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Twenty percent of US adults currently live with chronic 
non- cancer pain, and the prevalence of chronic low back 
pain in US adults aged 20–69 years old is estimated to 
be 13%.5 6 Similarly, 19% of adult Europeans are affected 
by chronic pain of moderate to severe intensity, among 
whom approximately half report back pain.7
Clinicians frequently offer patients non- surgical inter-
ventional procedures such as epidural steroid injections, 
medial branch blocks and radiofrequency ablation for 
the management of chronic non- cancer spinal pain.8 9 
However, clinical practice guidelines provide conflicting 
recommendations regarding their use. The 2009 Amer-
ican Pain Society guideline found insufficient evidence 
to make recommendations for the use of most interven-
tional procedures.10 In 2013, the American Society of 
Interventional Pain Physicians (ASIPP) stated there was 
fair to good evidence to support the use of many interven-
tional therapies for chronic spinal pain.1 11 In 2016, the 
National Institute for Health and Care Excellence (NICE) 
recommended against spinal injections for managing low 
back pain,12 and in 2018 the UK National Health Services 
proposed to defund injections for non- specific low 
back pain without sciatica due to the lack of supporting 
evidence.13 In 2020, NICE updated their guideline and 
reaffirmed this recommendation.14 In 2020, the ASIPP 
released their updated guideline reaffirming recommen-
dations in favour of radiofrequency ablation, nerve blocks 
and facet joint injections for chronic neck, mid- back 
and low back pain,15 and in 2021 the ASIPP published 
guidelines recommending epidural steroid injections for 
chronic spinal pain secondary to disc herniation, spine 
stenosis, discogenic pain and postsurgery syndrome.16
There are several conventional systematic reviews that 
have explored the effectiveness of interventional proce-
dures for chronic non- cancer spinal pain17–19; however, 
they do not explore the relative effectiveness of competing 
interventions. Two systematic reviews with network meta- 
analysis (NMA) have focused on interventional proce-
dures for spinal pain,20 21 but each combined acute and 
chronic pain complaints and none assessed the overall 
certainty of the evidence. Thus, we propose to conduct a 
systematic review and NMA of randomised trials to assess 
the comparative effectiveness and harms of available 
interventional procedures for the treatment of patients 
with chronic, axial or radicular, non- cancer, spinal pain.
METHODS
Standardised reporting and registration
We prepared our protocol in accordance with the 
Preferred Reporting Items for Systematic Review and 
Meta- Analysis Protocols checklist.22
Eligibility criteria
We will include randomised trials that: (1) enrolled 
participants among which at least 80% were adult patients 
(≥18 years old) presenting with chronic, axial and/or 
radicular, non- cancer spine pain (pain with ≥12 weeks 
duration or defined by authors as ‘chronic’) and (2) 
randomised patients to alternative, currently available, 
interventional procedures or to an interventional proce-
dure and a placebo/sham procedure or usual care. We 
will include trials that allowed co- interventions, if patients 
in all study arms received the same co- interventions (eg, 
exercise, physiotherapy). Table 1 provides further details 
of our inclusion and exclusion criteria.
Data sources and search strategy
An experienced medical librarian (RJC) developed 
and refined our search strategy for individual databases 
(online supplemental appendix 1). We will conduct 
our systematic searches for eligible studies in Medline, 
EMBASE, Cumulative Index to Nursing and Allied 
Health Literature (CINAHL), Cochrane Central Register 
of Controlled Trials (CENTRAL) and Web of Science 
without language restrictions. We will review the refer-
ence lists of included trials and relevant reviews for addi-
tional eligible studies.
Study selection
Pairs of trained reviewers will screen titles and abstracts 
of identified citations independently and in duplicate, 
using a standardised, pilot- tested form. Subsequently, 
reviewers will assess full texts of potentially eligible 
studies. Reviewers will resolve any disagreements through 
discussion or by adjudication with a third reviewer. We 
will use DistillerSR, an online systematic review software 
(Evidence Partners, Ottawa, Canada; http:// systematic- 
review. net) for screening titles and abstracts and full- text 
articles. We will contact study authors if limitations in 
reporting lead to uncertainties in eligibility.
Data extraction
We designed a standardised form and a detailed instruc-
tion manual for data abstraction. We will conduct calibra-
tion exercises prior to starting the abstraction process to 
promote consistency and accuracy of extracted data. Six 
pairs of reviewers will extract data independently and in 
duplicate.
For all included studies, reviewers will abstract the 
following data: study characteristics (eg, bibliographic 
information, country of origin, funding source), partic-
ipant characteristics (eg, sample size, age and sex of 
participants, location and severity of pain, clinical diag-
nosis, duration of pain, the proportion of patients 
involved in litigation or receiving disability benefits), 
characteristics of interventions and comparators (eg, 
number and frequency of procedures, overall treatment 
duration, length of follow- up), characteristics of health-
care providers (eg, experience performing interven-
tional procedures or formal certification), use of image 
guidance and patient- important outcomes as guided 
by the Initiative on Methods, Measurement, and Pain 
Assessment in Clinical Trials recommendations,23–25 
including pain intensity, physical functioning, emotional 
functioning, role functioning, social functioning, sleep 
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quality, return to work, opioid use and adverse events. 
All abstracted information will be recorded in an excel 
spreadsheet (Microsoft Office Excel 2019). We will 
contact the authors of included trials for unreported 
data or additional details when necessary. We will investi-
gate the potential clinical and statistical heterogeneity of 
non- interventional control arms (eg, usual care, standard 
care, exercise) to determine whether to consider them as 
a single node.
A preliminary literature search suggests there will 
be approximately 100 trials eligible for this review, and 
figures 1 and 2 illustrate potential networks of treatments 
that may be developed.
Risk of bias assessment
Pairs of reviewers will independently assess the risk of bias 
(RoB) among eligible studies using a modified Cochrane 
risk of bias instrument, which includes response options 
of ‘definitely yes’ and ‘probably yes’ (assigned low RoB), 
and ‘probably no’ and ‘definitely no’ (assigned high 
RoB). A revised Cochrane tool has been published (RoB 
2); however, formal testing has found low interrater reli-
ability and challenges in applying this instrument.26 We 
will assess the following RoB criteria: random sequence 
generation; allocation concealment; blinding of partic-
ipants, healthcare providers, data collectors, outcome 
assessor/adjudicator and incomplete outcome data 
(≥20% missing data will be considered high RoB).27 Any 
disagreements between reviewers will be resolved through 
discussion or with the help of an adjudicator.
Data synthesis
For direct comparisons, we will pool all outcomes reported 
by at least two trials addressing the same comparison. 
We will narratively describe study results if quantitative 
synthesis is not possible. For dichotomous outcomes that 
are reported by >1 randomised controlled trial (RCT), 
we will calculate the relative risk (RR) and the associated 
95% CIs to inform relative effectiveness.
For continuous outcomes that are reported by >1 RCT, 
we will calculate the weighted mean difference and 
associated 95% CI. We will use the methods described 
in Cochrane Handbook28 and by Hozo et al29 to impute 
means and SDs when only median, range and sample size 
are reported, or to impute the SD when the SE or SD 
for the differences are not reported and we are unable 
Table 1 Study eligibility criteria
Inclusion criteria Exclusion criteria
Population  ► Adult patients (≥18 years old) presenting with chronic, spinal 
non- cancer pain (pain with duration >12 weeks or defined by 
authors as ‘chronic’).
 ► Spinal non- cancer pain conditions include: neck pain, low 
back pain (with/without radicular lower extremity pain), cervical 
facet joint pain, sacroiliac joint related pain, lumbar radicular 
pain, cervical radicular pain, cervicogenic headaches, pain 
from spinal stenosis, discopathy (such as disc herniation, 
disc degeneration), spondylarthrosis, facet joint syndrome, 
radiculopathy, failed back surgery syndrome, persistent 
postsurgical spinal pain, whiplash- associated disorder.
 ► Acute and subacute pain (duration of 
pain <12 weeks)
 ► Children (age <18 years)
 ► Surgical patients (surgical pain)
Intervention  ► Cervical facet joint procedures (injection/nerve block)
 ► Cervical epidural injections (interlaminar/transforaminal)
 ► Cervical facet joint denervation/ radiofrequency ablation
 ► Lumbar epidural injection (interlaminar/transforaminal/caudal)
 ► Lumbar facet joint procedures (injection/ nerve block)
 ► Lumbar facet joint denervation radiofrequency ablation
 ► Sacroiliac joint procedures (injection/ nerve block)
 ► Sacroiliac joint denervation/ radiofrequency ablation
 ► Paravertebral injections (eg, trigger point injections)
Medications we have identified as candidates for injection include:
 ► Corticosteroids (eg, dexamethasone, hydrocortisone, 
prednisolone, triamcinolone, betamethasone, 
methylprednisolone)
 ► Anaesthetics (eg, bupivacaine, carbocaine, lidocaine, 
prilocaine, levobupivacaine, mepivacaine, ropivacaine)
 ► Any combination of steroids and anaesthetics
 ► Rami communicans block or 
radiofrequency lesioning
 ► Intradiscal electrothermal therapy (IDET)
 ► Chemonucleolysis
 ► Injection of methylene blue
 ► Prolotherapy
 ► Injection of platelet- rich plasma, stem 
cells or any other proposed regenerative 
substance
Comparator A different interventional procedure, usual care, sham procedure
Follow- up 
time
We will only include RCTs with a minimum follow- up time of 
1 month.
RCT, randomised controlled trial.
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to acquire these details from trial authors. For contin-
uous outcomes, when studies report effect estimates 
using different measurement instruments that capture a 
common construct (eg, pain), we will first transform all 
outcomes to a common instrument score.30
We will use change scores from baseline to the end of 
follow- up to account for interpatient variability. If change 
scores are not reported, we will calculate them using the 
baseline and end- of- study scores and the associated SDs 
using a correlation coefficient derived from the largest 
trial at the lowest RoB that reported a change score. We 
will use DerSimonian- Laird random- effects models for 
meta- analysis of all direct comparisons. For all direct 
comparisons, when there are at least 10 trials contrib-
uting to a meta- analysis, we will assess small study effects 
using Harbord’s test for binary outcomes and Egger’s test 
for continuous outcomes.31
We will perform NMA using a frequentist random- 
effects model applying the methodology of multivariable 
meta- analysis.32 33 We will use the ‘design- by- treatment’ 
model (global test) to assess the coherence assumption 
for each network.32 We will use the side splitting method 
to evaluate local (loop- specific) incoherence34 35 in each 
closed loop of the network as the difference between 
direct and indirect evidence. If we find significant inco-
herence in the network, we will perform NMA using an 
inconsistency model. We will explore the network for the 
source(s) of incoherence and further expand or exclude 
the node(s) introducing incoherence into the network.
When networks are sparse, random- effects models may 
generate noncredible wide CIs for the network estimates 
even when the direct and indirect estimates are coherent 
(ie, the CI of the network estimate is wider than both the 
estimates of precision associated with the direct and indi-
rect effect estimates).36 We will use a fixed- effect model 
for pooling in such cases. We will not perform NMA when 
10 or fewer studies report an outcome.
We will co- present the minimally important difference 
(MID) for all pooled effect estimates for continuous 
outcomes to optimise interpretability. The MID is the 
smallest change in an outcome that patients perceive as 
important.37 We will identify anchor- based MIDs for all 
continuous outcome measures pooled in our analysis. In 
cases in which more than one MID is identified, we will 
evaluate their credibility using the instrument by Devji T 
et al and select the most credible estimate.38 39
We will use the network estimate of treatment effects to 
calculate the risk difference (RD) for achieving the MID. 
Specifically, for each individual study, we will assume that 
the SDs of outcome measurements are the same in both 
the treatment and control groups, and that change scores 
in both groups are normally distributed. We will use the 
median or mean, and SD of the control group, with the 
established MID for the outcome in question to estimate 
Figure 1 Model network of possible pairwise comparisons 
of interventional procedures for chronic axial spine pain (from 
a preliminary search of the literature). LA, local anaesthetic, 
including lidocaine, bupivacaine, ropivacaine, carbocaine; 
S, steroids, including betamethasone, methylprednisolone, 
triamcinolone, dexamethasone, hydrocortisone; conservative: 
conservative therapies, including oral analgesics, exercise, 
standard treatment as per described; JI, joint injection (facet 
intraarticular injection or medial branch injection, or sacroiliac 
joint injection); RF, radiofrequency ablation (joint RF is 
radiofrequency ablation for the facet joint or sacroiliac joint, 
DRG RF is radiofrequency ablation of dorsal root ganglion); 
EI, epidural injection (transforaminal epidural, interlaminar 
epidural or caudal epidural); ParaI, paravertebral injection; 
TPI, trigger point injection; MI, intramuscular injection along 
the spine.
Figure 2 Model network of possible pairwise comparisons 
of interventional procedures for chronic radicular spine 
pain (from a preliminary search of the literature). LA, local 
anaesthetic, including lidocaine, bupivacaine, ropivacaine, 
carbocaine; S, steroids, including betamethasone, 
methylprednisolone, triamcinolone, dexamethasone, 
hydrocortisone; conservative: conservative therapies, 
including oral analgesics, exercise, standard treatment as 
per described; JI, joint injection (facet intraarticular injection 
or medial branch injection, or sacroiliac joint injection); 
RF, radiofrequency ablation (joint RF is radiofrequency 
ablation for the facet joint or sacroiliac joint, DRG RF is 
radiofrequency ablation of dorsal root ganglion); EI, epidural 
injection (transforaminal epidural, interlaminar epidural or 
caudal epidural); ParaI, paravertebral injection.
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the probability of achieving ≥MID in the control group. 
We will use the pooled mean difference to estimate the 
mean in the treatment group and calculate the proba-
bility of achieving ≥MID in the treatment group. Finally, 
we will use risks in both groups to acquire the RD for 
achieving ≥MID. To generate measures of absolute effec-
tive (RD) for binary outcomes, we will use estimates of 
baseline risk from the control arm of eligible trials.
NMAs typically estimate ranking probabilities among 
competing therapies using the surface under the cumu-
lative ranking curve (SUCRA), mean ranks and ranko-
grams. An intervention with an SUCRA value of 100 is 
considered the most effective, whereas an intervention 
with 0 is the least effective.40 However, SUCRA values 
are mostly dependent on the point estimate of effect 
and ignore the associated precision and certainty of 
evidence. Thus, we will apply a minimally- contextualised 
approach41 42 to convey the relative effectiveness of avail-
able interventional pain procedures. Specifically, for each 
outcome, we will place interventions in categories from 
best to worst based on the treatment effect estimates for 
benefits and harms obtained from NMA, and their associ-
ated certainty of evidence.
For categorisation of interventions, we will use the 
following approach. For each effectiveness outcome, we 
will create groups of interventions as follows: (1) The 
reference intervention (placebo/sham procedure) and 
interventions no different from placebo, which we refer 
to as ‘among the least effective’; (2) Interventions supe-
rior to placebo but not superior to other intervention(s), 
which we describe as ‘inferior to the most effective, but 
superior to the least effective’ (category 2 interventions) 
and (3) Interventions that prove superior to at least one 
category 2 intervention (which we define as ‘among 
the most effective’). We will use the same approach for 
adverse events but will create groups of interventions 
as follows: (1) no more harmful than placebo; (2) less 
harmful than some alternatives, but more harmful than 
placebo and (3) among the most harmful. For both bene-
fits and harms, we will then categorise interventions as 
those with moderate or high certainty, and those with low 
or very low certainty of evidence relative to placebo.43
We will use STATA V.16.0 (StataCorp) for all analyses. 
All comparisons will be two tailed using a threshold 
p≤0.05.
Subgroup analysis
We will use the Q statistic and I2 to explore statistical 
heterogeneity for direct meta- analysis, and five a priori 
hypotheses to explain heterogeneity between trials: (1) 
different clinical conditions (eg, neuropathic, nocicep-
tive, nociplastic pain, as defined by the International 
Association for the Study of Pain44 will show different 
treatment effects; (2) studies at higher RoB will show 
larger treatment effects; (3) shorter follow- up will show 
larger treatment effects than longer follow- up times; (4) 
patients receiving disability benefits or engaged in litiga-
tion will show smaller treatment effects45 and (5) using 
a positive response on diagnostic screening as an entry 
criteria for participants vs not will be associate with larger 
treatment effects. We will perform subgroup analyses 
regardless of heterogeneity estimates if there are at least 
two trials in each subgroup.
Assessing certainty of the evidence
We will use the Grading of Recommendations Assess-
ment, Development and Evaluation (GRADE) approach 
to assess the certainty of the direct, indirect and the 
network estimate for all outcomes. The starting point for 
certainty of evidence for randomised trials is high, and 
the direct evidence can be rated down for: RoB, incon-
sistency, indirectness or small study effects.46 Certainty 
ratings of indirect estimates start at the lowest GRADE 
rating of the direct comparisons that contributed to 
the most- dominant first order loop with further rating 
down for intransitivity when present.47 48 We will assess 
the imprecision at the network level. If incoherence is 
present, we will rate down the certainty of the network 
estimates. The certainty of evidence for network esti-
mate will be informed by the higher rating of the direct 
and indirect evidence.47 We will categorise certainty in 
evidence as high, moderate, low or very low.
Patient and public involvement
No patients were involved in the development of this 
protocol. However, patient partners will be included in 
the accompanying BMJ Rapid Recommendation which 
will provide contextualised clinical guidance based on 
this evidence synthesis.
DISCUSSION
Interventional pain procedures are increasingly used 
to manage chronic non- cancer spinal pain. In Ontario, 
Canada, physician billings for interventional procedures 
more than doubled from 2011 to 201549; however, this is 
a controversial treatment.50 Many jurisdictions, including 
Canada,51 have no standards for interventional proce-
dure training and practice. A 2016/2017 survey of Cana-
dian physicians practicing pain medicine found that 
only 37% of respondents believed that their colleagues 
provided interventional procedures in accordance with 
the best current evidence.52 Moreover, current guidelines 
for interventional procedures provide conflicting recom-
mendations.12 13 16 As such, there is an urgent need for 
a high- quality review to summarise the evidence for the 
effectiveness and harms associated with interventional 
procedures for chronic spinal pain.
Our study will have several strengths in relation to 
existing reviews. First, we will explore the comparative 
effectiveness of all currently available interventional 
procedures for patients with chronic, non- cancer, axial 
or radicular, spinal pain. Second, rather than restricting 
by condition, we will investigate whether the effects of 
treatment vary across neuropathic, nociceptive and noci-
plastic pain. Third, we will use the GRADE approach to 
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evaluate the certainty of evidence supporting treatment 
effects and use state- of- the- art methodology to summarise 
the relative effectiveness of competing interventions. A 
potential limitation will be the nature of available treat-
ment comparisons to build robust networks for analyses. 
The findings of our review will help inform patients with 
chronic non- cancer spinal pain about the role of inter-
ventional pain procedures, and identify key areas for 
research. This systematic review will also inform a BMJ 
Rapid Recommendations—a collaborative effort from the 
MAGIC Evidence Ecosystem Foundation ( www. magicevi-
dence. org) and BMJ—that will provide contextualised 
clinical guidance based on this body of evidence.
Ethics and dissemination
No research ethics approval is required for this system-
atic review, as no confidential patient data will be used. 
We will disseminate our findings through publication in a 
peer- reviewed journal and conference presentations, and 
our review will support development of an international 
clinical practice guideline.
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